Browse drugs

…rveillance, suggesting durable antitumor activity. Furthermore, ATAPL1 overcame chemotherapy resistance and exhibited superior therape…

…arched. All randomised controlled clinical trials investigating Finerenone combined with SGLT2i for DKD treatment will be included. Data e…

…mprehensive analysis of emerging strategies that aim to advance OralFMT by: (1) refining processing technologies (eg, lyophilisation) t…

…t 3 months postoperatively. All patients will receive life-long aspirin treatment after the first year. All of the patients will be req…

…articipants with resectable HCC received 2 doses of neoadjuvant cemiplimab 350 mg IV every 3 weeks before surgical resection and 8 cycles …

…ility, pharmacokinetics, and preliminary anti-tumor efficacy of HF50. The trial enrolls patients with advanced HER2-positive or HER2…

…2 in advanced solid tumors with high rates of TROP2 expression. MT-302 was delivered off the shelf with intravenous administration (an…

…an immunosuppressive to an immunoreactive phenotype.Conclusions HF1K16 monotherapy demonstrates a durable clinical signal in recurrent…

…y people globally, requiring alternative management strategies. Psilocybin is gaining attention for its potential in chronic pain manageme…

…fold in UISO versus untreated cells (figure 2A, B). Delivery of CIITA via NPs significantly enhanced both class I and class II antige…

…) RNA-LPA + IL-1R blockade, 4) RNA-LPA + IL-6R blockade, and 5) RNA-LPA + combination blockade. Peripheral blood following 5th vaccine …

…e clinical antitumor effect of microbial Nrf2 agonists, such as formate, in immunotherapy-resistant cancer patients.…